Ilex clofarabine gets user fee extension
Executive Summary
FDA extends review clock for Ilex' pediatric leukemia agent clofarabine by three months to Dec. 30 following submission of additional clinical data. Ilex completed the rolling NDA filing March 29 for priority review, originally setting a Sept. 29 user fee date. Ilex submitted data on 14 additional patients from Phase II trials in acute lymphoblastic leukemia and acute myeloid leukemia, bringing the total number of patients included in the filing to 84. Genzyme, which is seeking regulatory clearance to acquire Ilex, has conservatively projected approval for late 2005...
You may also be interested in...
Ilex Clolar Advisory Committee Splits On Pediatric Leukemia Approvals
FDA's Oncologic Drugs Advisory Committee recommended accelerated approval for Ilex' Clolar (clofarabine) in the treatment of pediatric acute lymphoblastic leukemia, but not pediatric acute myelogenous leukemia, at its Dec. 1 meeting
Day One Springs Into Commercial Action With Ojemda Approval
The company is targeting around 200 centers that treat the vast majority of the few thousand pediatric low-grade glioma patients who are candidates for the RAF-targeting drug.
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.